Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Italian Diagnostic Developer Calls Luminex a 'Perfect Fit'
04:43pm, Monday, 12'th Apr 2021
Investors reacted favorably over the announcement that Saluggia, Italy-based DiaSorin SpA (MIL:DIA) is paying $1.8 billion to purchase Austin, Texas-based Luminex Corp. (NASDAQ:LMNX), a developer of p
FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
01:20pm, Monday, 12'th Apr 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the com
Basel, 12 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability of the investigational antibody cocktail casiriv
New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio
01:00am, Thursday, 08'th Apr 2021
Basel, 8 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at t
Roche, Merck and J&J: Kings of R&D Spenders in 2020
10:26am, Wednesday, 07'th Apr 2021
A common saying among investors is that you have to spend money to make money. If that's the case, the top R&D spenders in the pharmaceutical industry should have a high potential to be among the lead
Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cancer types
01:00am, Wednesday, 07'th Apr 2021
Basel, 07 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys Anti-p53 immunoassay for the in vitro quantitative determination of anti-p53 antibodies. This test i
Oncimmune Holdings wins COVID-19 contracts with Roche and Cedars-Sinai Medical Center
03:13am, Tuesday, 06'th Apr 2021
Oncimmune Holdings PLC (LON:ONC) said it landed two substantial new contracts for an infectious disease panel that helps predict the severity of Coronavirus (COVID-19) along with the potential effec
Oncimmune Holdings lands contracts with Roche Pharmaceuticals and the world-famous Cedars-Sinai Medical Center
02:59am, Tuesday, 06'th Apr 2021
Oncimmune Holdings PLC (LON:ONC) has landed two substantial new contracts for an infectious disease panel that can help predict the severity of COVID-19 along with the potential effectiveness of vacci
ARK Genomic Revolution Multi-Sector ETF: Poised For Continued Underperformance
07:27am, Friday, 02'nd Apr 2021
ARK Genomic Revolution Multi-Sector ETF: Poised For Continued Underperformance
This 2020 Biotech IPO Is Poised to Break Out in 2021
06:15am, Friday, 02'nd Apr 2021
Revolution Medicines' leading compound is shaping up to be a platform in a pill.
Roche launches Elecsys Epstein-Barr Virus (EBV) immunoassay panel to improve EBV infection staging
01:00am, Wednesday, 31'st Mar 2021
Basel, 31 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Elecsys® EBV panel has launched in countries accepting the CE Mark. Roche will file for approval with the FDA in the
Roche's (RHHBY) SMA Treatment Evrysdi Secures EC Approval
01:51pm, Tuesday, 30'th Mar 2021
Roche (RHHBY) gains a regulatory nod for its SMA treatment Evrysdi in Europe for patients aged two months and above.
Johnson & Johnson, Roche and Novartis Top in Pharma Sales
10:16am, Tuesday, 30'th Mar 2021
Johnson & Johnson's (NYSE:JNJ) 2020 revenue topped all pharmaceutical companies, according to rankings published by Fierce Pharma.
PTC Therapeutics-Roche's Evrysdi Approved In Europe For Muscular Atrophy
07:05am, Tuesday, 30'th Mar 2021
The European Commission (EC) has granted marketing authorization to PTC Therapeutics Inc's (NASDAQ: PTCT) Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in patients two mo
Roche's Evrysdi approved by European Commission as first and only at home treatment for spinal muscular atrophy
01:00am, Tuesday, 30'th Mar 2021
Basel, 30 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has approved Evrysdi™ (risdiplam) for the treatment of 5q spinal muscular atrophy (SMA) in
